Andersson NW, et al. - Researchers used the antimalaria 4-aminoquinoline drugs chloroquine and hydroxychloroquine (HCQ) in the treatment of a wide range of CTDs. Furthermore, 4-aminoquinoline–exposed pregnancies were identified from a cohort of 1 240 875 pregnancies to evaluate the associated risks of major birth defects, preterm birth, and small size for gestational age (SGA) in a Danish nationwide cohort study from 1996 through 2016. Via prevalence odds ratios estimated through logistic regression, the relationship with the outcomes was evaluated. They individually evaluated associated risks for chloroquine and HCQ through additional analyses. They identified a sum of 1487 pregnancies exposed to 4-aminoquinolines (1184 chloroquine- and 303 HCQ-exposed). No elevated risk of major birth defects, preterm birth, or SGA was distinguished among pregnancies exposed to 4-aminoquinolines (chloroquine and HCQ).